blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2212423

EP2212423 - POXVIRAL ONCOLYTIC VECTORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.12.2015
Database last updated on 15.07.2024
Most recent event   Tooltip20.07.2018Lapse of the patent in a contracting state
New state(s): PT		published on 22.08.2018  [2018/34]
Applicant(s)For all designated states
Transgene SA
Boulevard Gonthier d`Andernach Parc d`Innovation, CS80166
67405 Illkirch Graffenstaden Cedex / FR
[2010/31]
Inventor(s)01 / ERBS, Philippe
134 rue du Cottey
F-01120 Dagneux / FR
02 / FOLOPPE, Johann
41 rue du Lazaret
F-67100 Strasbourg / FR
 [2010/31]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[N/P]
Former [2015/07]Vossius & Partner
Siebertstrasse 3
81675 München / DE
Former [2010/31]Vossius & Partner
Siebertstrasse 4
81675 München / DE
Application number, filing date08851361.917.11.2008
[2010/31]
WO2008EP09721
Priority number, dateEP2007030155619.11.2007         Original published format: EP 07301556
[2010/31]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2009065547
Date:28.05.2009
Language:EN
[2009/22]
Type: A2 Application without search report 
No.:EP2212423
Date:04.08.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 28.05.2009 takes the place of the publication of the European patent application.
[2010/31]
Type: B1 Patent specification 
No.:EP2212423
Date:11.02.2015
Language:EN
[2015/07]
Search report(s)International search report - published on:EP09.07.2009
ClassificationIPC:C12N15/86, A61K35/76
[2010/31]
CPC:
A61K35/768 (EP,US); C12N15/863 (KR); A61K38/45 (EP,US);
A61K38/50 (EP,US); A61P35/00 (EP); A61P43/00 (EP);
C07K14/005 (EP,US); C12N15/86 (EP,US); C12N2710/24122 (EP,US);
C12N2710/24132 (EP,US); C12N2710/24143 (EP,US) (-)
C-Set:
A61K35/768, A61K2300/00 (US,EP);
A61K38/45, A61K2300/00 (US,EP);
A61K38/50, A61K2300/00 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2010/31]
Extension statesALNot yet paid
BANot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:ONKOLYTISCHE POXVIRUS-VEKTOREN[2010/31]
English:POXVIRAL ONCOLYTIC VECTORS[2010/31]
French:VECTEURS ONCOLYTIQUES POXVIRAUX[2010/31]
Entry into regional phase30.03.2010National basic fee paid 
30.03.2010Designation fee(s) paid 
30.03.2010Examination fee paid 
Examination procedure02.09.2009Request for preliminary examination filed
International Preliminary Examining Authority: EP
30.03.2010Amendment by applicant (claims and/or description)
30.03.2010Examination requested  [2010/31]
13.05.2013Despatch of a communication from the examining division (Time limit: M04)
28.08.2013Reply to a communication from the examining division
18.02.2014Despatch of a communication from the examining division (Time limit: M04)
11.04.2014Reply to a communication from the examining division
11.09.2014Communication of intention to grant the patent
18.12.2014Fee for grant paid
18.12.2014Fee for publishing/printing paid
18.12.2014Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.05.2013
Opposition(s)12.11.2015No opposition filed within time limit [2016/03]
Fees paidRenewal fee
24.11.2010Renewal fee patent year 03
23.11.2011Renewal fee patent year 04
23.11.2012Renewal fee patent year 05
25.11.2013Renewal fee patent year 06
24.11.2014Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipBG11.02.2015
CY11.02.2015
EE11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
PT11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
GR12.05.2015
IS11.06.2015
[2018/34]
Former [2017/39]BG11.02.2015
CY11.02.2015
EE11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
MT11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
TR11.02.2015
GR12.05.2015
IS11.06.2015
Former [2016/28]EE11.02.2015
LT11.02.2015
LV11.02.2015
MC11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
GR12.05.2015
IS11.06.2015
Former [2016/12]EE11.02.2015
LT11.02.2015
LV11.02.2015
RO11.02.2015
SI11.02.2015
SK11.02.2015
GR12.05.2015
IS11.06.2015
Former [2015/49]EE11.02.2015
LT11.02.2015
LV11.02.2015
RO11.02.2015
SK11.02.2015
GR12.05.2015
IS11.06.2015
Former [2015/39]LT11.02.2015
LV11.02.2015
GR12.05.2015
IS11.06.2015
Former [2015/38]LT11.02.2015
GR12.05.2015
IS11.06.2015
Former [2015/37]LT11.02.2015
GR12.05.2015
Former [2015/35]LT11.02.2015
Cited inInternational search[X]EP1367128  (CONNAUGHT TECHNOLOGY CORP [US]) [X] 1,3-5,19,20 * paragraph [0328] *;
 [X]  - PERKUS M E ET AL, "DELETION OF 55 OPEN READING FRAMES FROM THE TERMINI OF VACCINIA VIRUS", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, (19910101), vol. 180, ISSN 0042-6822, pages 406 - 410, XP000351448 [X] 1,3-5,19,20 * the whole document *

DOI:   http://dx.doi.org/10.1016/0042-6822(91)90047-F
 [A]  - ZHANG Q ET AL, "Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD.; US, (20071015), vol. 67, no. 20, ISSN 0008-5472, pages 10038 - 10046, XP002505303

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-07-0146
 [A]  - ERBS P ET AL, "Modified vaccinia virus Ankara as a vector for suicide gene therapy", CANCER GENE THERAPY, (20071109), vol. 15, no. 1, ISSN 0929-1903, pages 18 - 28, XP002524702

DOI:   http://dx.doi.org/10.1038/SJ.CGT.7701098
 [A]  - ROSEMAN NANCY A ET AL, "Purification and characterization of the vaccinia virus deoxyuridine triphosphatase expressed in Escherichia coli", JOURNAL OF BIOLOGICAL CHEMISTRY, (1996), vol. 271, no. 38, ISSN 0021-9258, pages 23506 - 23511, XP002524703

DOI:   http://dx.doi.org/10.1074/jbc.271.38.23506
 [PX]  - PRICHARD MARK N ET AL, "Vaccinia virus lacking the deoxyuridine triphosphatase gene (F2L) replicates well in vitro and in vivo, but is hypersensitive to the antiviral drug (N)-methanocarbathymidine", VIROLOGY JOURNAL, BIOMED CENTRAL, LONDON, GB, (20080305), vol. 5, no. 1, ISSN 1743-422X, page 39, XP021038341 [PX] 1,3,4,6,19,20 * the whole document *
 [PA]  - FOLOPPE J ET AL, "Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus", GENE THERAPY, (20080515), vol. 15, no. 20, ISSN 0969-7128, pages 1361 - 1371, XP002524704

DOI:   http://dx.doi.org/10.1038/GT.2008.82
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.